Deepika Kumar, MD
Assistant Professor of PathologyCards
Appointments
Additional Titles
Education Leader, Hematopathology, Pathology
Contact Info
Pathology
310 Cedar Street, PO Box 208023
New Haven, CT 06510
United States
Appointments
Additional Titles
Education Leader, Hematopathology, Pathology
Contact Info
Pathology
310 Cedar Street, PO Box 208023
New Haven, CT 06510
United States
Appointments
Additional Titles
Education Leader, Hematopathology, Pathology
Contact Info
Pathology
310 Cedar Street, PO Box 208023
New Haven, CT 06510
United States
About
Copy Link
Titles
Assistant Professor of Pathology
Education Leader, Hematopathology, Pathology
Biography
Deepika Kumar, MD, is an Assistant Professor of Pathology at Yale School of Medicine, who specializes in Hematopathology and Genitourinary pathology.
She earned her medical degree from Government Medical College, Aurangabad, and finished a pathology residency at Sion Hospital, University of Mumbai in India. She then completed residency training in Anatomic and Clinical Pathology at Yale New Haven Hospital, serving as chief resident during her final year. Afterward, she pursued fellowship training in Hematopathology and then Renal and Genitourinary pathology, both at Yale. She currently serves as the education leader for the Hematopathology division.
Her clinical expertise encompasses diagnosis of hematopoietic disorders and malignancies (lymphoma, leukemia, myeloma) and genitourinary malignancies (bladder, kidney, prostate, testis). Her academic interests include studying immune microenvironment and prognostic and predictive factors associated with hematologic and genitourinary malignancies. My interests in expert consultation include Hematopathology and Genitourinary pathology.
Appointments
Pathology
Assistant ProfessorPrimary
Other Departments & Organizations
- Genitourinary Pathology
- Hematopathology
- Hematopathology
- Pathology
- Yale Medicine
- Yale New Haven Health System
Education & Training
- Clinical Fellow
- Yale-New Haven Hospital (2022)
- Clinical Fellow
- Yale-New Haven Hospital (2021)
- Chief Resident
- Yale-New Haven Hospital (2020)
- Residency
- Yale-New Haven Hospital (2019) (2019)
- MD
- University of Mumbai, Pathology (AP/CP)
- Residency
- L.T.M.M.C (University of Mumbai)
- MD
- Government Medical School
Research
Copy Link
Overview
Medical Research Interests
ORCID
0009-0008-8470-3593
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Mina Xu, MD
Adebowale Adeniran, MD
Guoping Cai, MD, MS
David Rimm, MD, PhD
David Schoenfeld, MD, PhD
Demetrios Braddock, MD, PhD
Urinary Bladder Neoplasms
Publications
Featured Publications
Microenvironment Cell Contribution to Lymphoma Immunity
Kumar D, Xu ML. Microenvironment Cell Contribution to Lymphoma Immunity. Frontiers In Oncology 2018, 8: 288. PMID: 30101129, PMCID: PMC6073855, DOI: 10.3389/fonc.2018.00288.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricClinicopathological Review of Micropapillary Urothelial Carcinoma
Kumar D, Adeniran AJ. Clinicopathological Review of Micropapillary Urothelial Carcinoma. Current Oncology Reports 2022, 24: 603-610. PMID: 35199295, DOI: 10.1007/s11912-022-01219-x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsBenign lymph node microenvironment is associated with response to immunotherapy
Toki MI, Kumar D, Ahmed FS, Rimm DL, Xu ML. Benign lymph node microenvironment is associated with response to immunotherapy. Precision Clinical Medicine 2020, 3: 44-53. PMID: 35693430, PMCID: PMC8985791, DOI: 10.1093/pcmedi/pbaa003.Peer-Reviewed Original ResearchCitationsAltmetricPlasmacytoid dendritic cell clusters are associated with poor prognosis in chronic myelomonocytic leukemia
Kumar D, Cheng W, Lin L, Raess P, Xie W, Wong J, Daneshpajouhnejad P, Fathalla L, Morgan E, Bagg A, Hasserjian R, Katz S, Xu M. Plasmacytoid dendritic cell clusters are associated with poor prognosis in chronic myelomonocytic leukemia. Virchows Archiv 2025, 1-6. PMID: 41247506, DOI: 10.1007/s00428-025-04333-w.Peer-Reviewed Original ResearchCitationsAltmetric
2026
VEXAS Syndrome: Clues to Avoid Vexation
Kumar D, Panse G, Ko C. VEXAS Syndrome: Clues to Avoid Vexation. Journal Of Cutaneous Pathology 2026, 53: 862-868. PMID: 42219376, PMCID: PMC13432775, DOI: 10.1111/cup.70154.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2025
Clinicopathologic characteristics of lymphoproliferative disorders involving the kidney
Takeda K, Tang H, Kumar D, Adeniran A, Cai G. Clinicopathologic characteristics of lymphoproliferative disorders involving the kidney. American Journal Of Clinical Pathology 2025, 164: 192-199. PMID: 40418705, DOI: 10.1093/ajcp/aqaf023.Peer-Reviewed Original ResearchCitations
2024
A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models
Stabach P, Sims D, Gomez-BaƱuelos E, Zehentmeier S, Dammen-Brower K, Bernhisel A, Kujawski S, Lopez S, Petri M, Goldman D, Lester E, Le Q, Ishaq T, Kim H, Srivastava S, Kumar D, Pereira J, Yarema K, Koumpouras F, Andrade F, Braddock D. A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models. JCI Insight 2024, 9: e177003. PMID: 38888971, PMCID: PMC11383374, DOI: 10.1172/jci.insight.177003.Peer-Reviewed Original ResearchCitationsAltmetric
2022
Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance
Schoenfeld D, Merkin R, Moutafi M, Martinez S, Adeniran A, Kumar D, Jilaveanu L, Hurwitz M, Rimm D, Kluger H. Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance. Frontiers In Oncology 2022, 12: 990367. PMID: 36313654, PMCID: PMC9608089, DOI: 10.3389/fonc.2022.990367.Peer-Reviewed Original ResearchCitationsAltmetric
2021
Can primary hepatocellular carcinoma histomorphology predict extrahepatic metastasis?
Kumar D, Hafez O, Jain D, Zhang X. Can primary hepatocellular carcinoma histomorphology predict extrahepatic metastasis? Human Pathology 2021, 113: 39-46. PMID: 33905775, DOI: 10.1016/j.humpath.2021.04.008.Peer-Reviewed Original ResearchCitations
2019
Cryoglobulinemia as a Possible Primer for TRALI: Report of a Case
Beech C, Kumar D, Hendrickson J, Perincheri S, Tormey C, Bahar B. Cryoglobulinemia as a Possible Primer for TRALI: Report of a Case. Lab Medicine 2019, 50: 313-319. PMID: 30657960, DOI: 10.1093/labmed/lmy073.Peer-Reviewed Original ResearchCitationsAltmetric
News
Copy Link
News
Get In Touch
Copy Link
Contacts
Pathology
310 Cedar Street, PO Box 208023
New Haven, CT 06510
United States
Administrative Support
Locations
Brady Memorial Laboratory
Academic Office
310 Cedar St
New Haven, CT 06510